Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;10(2):180-192.
doi: 10.21037/hbsn-2021-7.

Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Ti Zhang  1 , Philippe Merle  2 , Huaqi Wang  3 , Haitao Zhao  4 , Masatoshi Kudo  5
Affiliations
Review

Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Ti Zhang et al. Hepatobiliary Surg Nutr. 2021 Apr.

Abstract

Importance: Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma (HCC), and consistently it is the hotspot in clinical studies.

Objective: To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies.

Evidence review: We searched PubMed, MEDLINE, Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC.

Findings: Several clinical issues are worth reconsidering, such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems, the translation of surrogate endpoint objective response rate (ORR) benefits into overall survival (OS) benefits, and whether conversion surgery contributes to initial expectations of long-term survival or not. New concepts in novel immunotherapy and targeted therapy in combination with loco-regional therapies may improve overall survival for HCC.

Conclusions and relevance for reviews: Comprehensive understanding of the mechanism of immunotherapy and targeted therapy contributes to better prognosis of advanced HCC and more explorative combination therapies are needed.

Keywords: Hepatocellular carcinoma (HCC); angiogenesis; combination therapy; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn-2021-7). Dr. TZ reports grants from National Science and Technology Major Project (No. 2017ZX10203207) and National Natural Science Foundation of China (No. 81672884). Dr. PM serves as a member of AdBoard from Roche, AstraZeneca, BMS, MSD, Eisai, Ipsen, Lilly, Bayer, and Research Grant from Ipsen. Dr. HZ serves as unpaid editorial board members of Hepatobiliary Surgery and Nutrition. Dr. MK reports Lecture fee/Honoraria from Eisai, Bayer, MSD, BMS, EA Pharma, Eli Lilly, Chugai; grant from Eisai, Takeda, Otsuka, Taiho, EA Pharma, Gilead Sciences, Abbvie, Sumitomo Dainippon Pharma, Chugai, Ono Pharmaceutical Co.; Grant/Contracts: research from Ono Pharmaceutical Co.) and Advisory Consulting fee from Eisai, Ono Pharmaceutical Co., MSD, BMS, Roche. The other author has no conflicts of interest to declare.

Comment in

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-66. 10.1111/liv.12818 - DOI - PMC - PubMed
    1. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst 2017;109:djx030. 10.1093/jnci/djx030 - DOI - PMC - PubMed
    1. Zhang B, Zhang B, Zhang Z, et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Sci China Life Sci 2018;61:660-70. 10.1007/s11427-017-9259-9 - DOI - PubMed
    1. Kudo M, Izumi N, Kubo S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2020;50:15-46. 10.1111/hepr.13438 - DOI - PMC - PubMed

LinkOut - more resources